Biohaven says taldefgrobep alfa receives EU orphan drug designation for SMA

Biohaven announced that it received orphan medicinal product designation from the European Commission for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy, or SMA. Irfan Qureshi, MD, Chief Medical Officer, Biohaven commented, “We are delighted that the European Commission granted orphan drug designation for taldefgrobep alfa for the treatment of SMA. Children and adults living with SMA experience significant muscle weakness and functional impairments affecting their quality of daily life, and a substantial unmet medical need persists. We are excited about the potential for taldefgrobep alfa to improve the lives of patients and families affected by SMA.”